Carboplatin has 13 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Fosphenytoin, Phenytoin, Topotecan. Patients taking Carboplatin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 13
- Major
- 3
- Moderate
- 5
- Minor
- 5
Major (3)
- Carboplatin + Fosphenytoin— Carboplatin decreases fosphenytoin serum levels, which may lead to exacerbation of seizures.
- Carboplatin + Phenytoin— Carboplatin decreases phenytoin serum levels, which may lead to exacerbation of seizures.
- Carboplatin + Topotecan— Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of …
Moderate (5)
- Carboplatin + Bevacizumab-Nwgd— No clinically meaningful effect on carboplatin pharmacokinetics; however, some patients receiving bevacizumab with pacli…
- Carboplatin + Bexarotene— Co-administration with paclitaxel increased bexarotene exposure 2-fold. No effect on carboplatin exposure when given alo…
- Carboplatin + Fosphenytoin Sodium— May decrease phenytoin serum levels; dose adjustment may be required.
- Carboplatin + Nephrotoxic Compounds— Renal effects of nephrotoxic compounds may be potentiated by carboplatin.
- Carboplatin + Phenytoin Sodium— May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
Minor (5)
- Carboplatin + Bevacizumab— No clinically meaningful effect on pharmacokinetics of carboplatin when administered with bevacizumab.
- Carboplatin + Bevacizumab-Adcd— No clinically meaningful effect on pharmacokinetics of carboplatin when administered with bevacizumab.
- Carboplatin + Bevacizumab-Awwb— No clinically meaningful effect on carboplatin pharmacokinetics observed when administered with bevacizumab.
- Carboplatin + Bevacizumab-Bvzr— No clinically meaningful effect on carboplatin pharmacokinetics observed when bevacizumab was administered in combinatio…
- Carboplatin + Bevacizumab-Maly— No clinically meaningful effect on the pharmacokinetics of carboplatin observed when bevacizumab was administered in com…